4[2]Moor ACE, Dubbelman TMAR, Van Steveninck, et al . Transfusiontransmitted diseases: risk, prevention and perspectives. Eur J Hamatol,1999,62( 1 ): 1-18.
5[4]Reichard O, Norkrans G, Fryden A, et al . Comparison of 3 quantitative HCV RNA assays,accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. Scand J Infect Dis, 1998,30(5):441-446.
6[5]Olmedo E, Costa J, Lopez-Labrador FX, et al . Comparative study of a modified competitive RT-PCR and Amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum. J Med Virol, 1999,58( 1 ) :35-43.
7[6]Horn T, Chang CA, Urdea MS. Chemical synthesis and characterization of branched oligodeoxyribonucleotides (bDNA) for use as signal amplifiers in nucleic acid quantification assays. Nucl Acids Res, 1997,25 (23): 4842-4849.
8[7]Holland P, Abramson R, Watson R, et al . Detectioon of specific polymerase chain reaction product by utilizing the 5'-3' exonuclease activity of thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA, 1991,88(16): 7276-7280.
9[8]Pisani G,Cristiano K,Saldanha J, et al .External quality assessment for the detection of blood-borne viruses in plasma by nucleic acid amplification technology: the first human immumodeficiency virus and hepatitis B virus studies (HIV EQA/1 and HBV EQA/1) and the fifth hepatitis C virus study (HCV EQA/5). Vox Sang,2004,87(2) :91-95.
10[9]Allan J. Genomic screening for blood-borne viruses in trmsfision settings.Clin Lab Haematol,2000,22( 1 ): 1-10.
